Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free MOLN Stock Alerts

Molecular Partners (MOLN) Financials

Molecular Partners logo
$4.05 +0.03 (+0.77%)
Closing price 07/10/2026 03:59 PM Eastern
Extended Trading
$4.16 +0.11 (+2.67%)
As of 07/10/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Molecular Partners

Annual Income Statements for Molecular Partners

This table shows Molecular Partners' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -38 -71 -70 133 -74 -60 -82
Consolidated Net Income / (Loss)		 -38 -71 -70 128 -74 -60 -78
Net Income / (Loss) Continuing Operations		 -38 -71 -70 128 -74 -60 -78
Total Pre-Tax Income 		-38 -71 -70 128 -74 -60 -78
Total Operating Income		 -38 -66 -69 126 -73 -68 -73
Total Gross Profit		 21 11 11 205 8.37 5.48 0.00
Total Revenue		 21 11 11 205 8.37 5.48 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 59 76 80 79 81 73 73
Selling, General & Admin Expense		 14 13 19 24 23 19 19
Research & Development Expense		 45 63 61 55 58 54 51
Restructuring Charge		 - - - - 0.00 0.00 3.39
Total Other Income / (Expense), net		 0.40 -5.02 -0.40 1.34 -1.04 7.91 -4.44
Interest Expense		 1.25 5.44 0.61 0.67 6.13 0.04 6.36
Interest & Investment Income		 1.65 0.41 0.21 2.01 5.09 7.96 1.92
Income Tax Expense		 0.02 -0.01 0.00 0.00 0.00 0.00 0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - -5.75 - - 4.80
Basic Earnings per Share		 - - - $3.93 ($2.25) ($1.75) ($2.08)
Weighted Average Basic Shares Outstanding		 - - 32.29M 36.04M 36.35M 40.36M 40.37M
Diluted Earnings per Share		 - - - $3.83 ($2.25) ($1.75) ($2.08)
Weighted Average Diluted Shares Outstanding		 - - 32.29M 36.04M 36.35M 40.36M 40.37M
Weighted Average Basic & Diluted Shares Outstanding		 - - 32.29M 36.04M 36.35M 40.36M 40.37M

Quarterly Income Statements for Molecular Partners

No quarterly income statements for Molecular Partners are available.

Annual Cash Flow Statements for Molecular Partners

This table details how cash moves in and out of Molecular Partners' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -24 66 -68 17 -23 -17 15
Net Cash From Operating Activities		 -5.34 -33 -100 127 -403 -322 -159
Net Cash From Continuing Operating Activities		 -5.34 -32 -100 127 -403 -322 -159
Net Income / (Loss) Continuing Operations		 -38 -71 -70 128 -74 -60 -78
Consolidated Net Income / (Loss)		 -38 -71 -70 128 -74 -60 -78
Depreciation Expense		 2.55 3.26 2.80 2.58 2.88 2.61 2.70
Non-Cash Adjustments To Reconcile Net Income		 -1.47 8.31 3.77 2.09 -330 -265 -84
Changes in Operating Assets and Liabilities, net		 31 27 -37 -5.16 -2.08 0.20 0.69
Net Cash From Investing Activities		 -21 -25 -24 -110 380 305 174
Net Cash From Continuing Investing Activities		 -21 -1.26 -24 -110 380 305 174
Sale and/or Maturity of Investments		 59 - 74 216 380 305 174
Net Cash From Financing Activities		 -0.23 128 55 -1.70 0.00 0.00 0.00
Net Cash From Continuing Financing Activities		 0.00 127 56 0.00 0.00 0.00 0.00
Cash Interest Received		 1.44 - 0.08 0.53 4.55 4.67 2.18

Quarterly Cash Flow Statements for Molecular Partners

No quarterly cash flow statements for Molecular Partners are available.

Annual Balance Sheets for Molecular Partners

This table presents Molecular Partners' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 212 189 284 236 175 129
Total Current Assets		 201 180 276 229 170 122
Cash & Equivalents		 151 79 95 80 70 104
Short-Term Investments		 45 67 174 142 94 13
Accounts Receivable		 3.20 28 1.10 2.32 2.56 2.31
Other Current Assets		 - 6.26 4.97 4.30 2.78 2.50
Plant, Property, & Equipment, net		 11 8.91 0.00 0.00 4.63 6.59
Total Noncurrent Assets		 0.39 0.36 0.29 0.25 0.05 0.00
Intangible Assets		 0.39 0.36 0.29 0.25 0.05 0.00
Total Liabilities & Shareholders' Equity		 212 189 284 236 175 129
Total Liabilities		 91 71 29 26 19 27
Total Current Liabilities		 65 51 19 17 12 14
Accounts Payable		 6.58 8.08 2.32 1.58 2.05 2.23
Accrued Expenses		 - - - - 8.50 10
Other Current Liabilities		 50 32 8.23 6.59 1.34 1.52
Total Noncurrent Liabilities		 26 20 11 8.93 6.73 14
Noncurrent Employee Benefit Liabilities		 15 7.37 2.76 6.02 5.38 10
Other Noncurrent Operating Liabilities		 3.32 7.57 3.94 - 1.35 3.27
Total Equity & Noncontrolling Interests		 121 117 254 210 156 101
Total Preferred & Common Equity		 121 117 254 210 -268 -389
Total Common Equity		 121 117 254 210 -268 -389
Common Stock		 341 392 394 439 4.45 5.09
Retained Earnings		 -220 -274 -138 -228 -272 -393
Treasury Stock		 - 0.00 -1.06 -1.17 -1.08 -1.42

Quarterly Balance Sheets for Molecular Partners

No quarterly balance sheets for Molecular Partners are available.

Annual Metrics And Ratios for Molecular Partners

This table displays calculated financial ratios and metrics derived from Molecular Partners' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 32,292,648.00 36,044,706.00 36,354,297.00 - 40,374,641.00
DEI Adjusted Shares Outstanding		 0.00 0.00 32,292,648.00 36,044,706.00 36,354,297.00 - 40,374,641.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -2.16 3.70 -2.03 - -2.04
Growth Metrics		 - - - - - - -
Profitability Metrics		 - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -27 -46 -49 126 -51 -47 -51
Return On Investment Capital (ROIC_SIMPLE)		 - - - 48.83% -23.91% -29.99% -50.65%
Earnings before Interest and Taxes (EBIT)		 -38 -66 -69 126 -73 -68 -73
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -35 -63 -67 129 -70 -65 -71
Valuation Ratios		 - - - - - - -
Leverage & Solvency		 - - - - - - -
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 15 -98 125 -54 -51 -44
Efficiency Ratios		 - - - - - - -
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 -61 -12 -11 -7.32 -3.38 -16
Increase / (Decrease) in Invested Capital		 0.00 -61 49 0.81 3.57 3.94 -7.43
Book Value per Share		 $0.00 $40.36 $3.63 $7.88 $5.82 $4.30 ($9.64)
Tangible Book Value per Share		 $0.00 $40.23 $3.62 $7.87 $5.82 $4.30 ($9.64)
Total Capital		 0.00 128 123 258 213 158 101
Total Debt		 0.00 6.82 5.30 3.95 2.91 1.35 0.00
Total Long-Term Debt		 0.00 6.82 5.30 3.95 2.91 1.35 0.00
Net Debt		 0.00 -189 -140 -266 -219 -163 -117
Capital Expenditures (CapEx)		 1.07 1.90 1.02 1.27 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -60 -17 -13 -11 -6.55 -9.08
Debt-free Net Working Capital (DFNWC)		 0.00 136 128 257 212 158 108
Net Working Capital (NWC)		 0.00 136 128 257 212 158 108
Net Nonoperating Expense (NNE)		 11 25 21 -1.34 23 12 26
Net Nonoperating Obligations (NNO)		 0.00 -182 -129 -265 -217 -160 -117
Total Depreciation and Amortization (D&A)		 2.55 3.26 2.80 2.58 2.88 2.61 2.70
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $3.63 ($1.89) ($1.75) ($2.08)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 32.29M 36.04M 36.35M 40.36M 40.37M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $3.54 ($1.89) ($1.75) ($2.08)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 32.29M 36.04M 36.35M 40.36M 40.37M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 32.29M 36.04M 36.35M 40.36M 40.37M
Normalized Net Operating Profit after Tax (NOPAT)		 -27 -46 -49 88 -51 -47 -49
Debt Service Ratios		 - - - - - - -
Payout Ratios		 - - - - - - -

Quarterly Metrics And Ratios for Molecular Partners

No quarterly metrics and ratios for Molecular Partners are available.


Financials Breakdown Chart

Molecular Partners Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Molecular Partners' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Molecular Partners' net income appears to be on an upward trend, with a most recent value of -$77.69 million in 2025, rising from -$37.52 million in 2019. The previous period was -$59.60 million in 2024. Find out what analysts predict for Molecular Partners in the coming months.

Molecular Partners' total operating income in 2025 was -$73.24 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $73.24 million

Over the last 6 years, Molecular Partners' total revenue changed from $21.07 million in 2019 to $0.00 in 2025, a change of -100.0%.

Molecular Partners' total liabilities were at $27.43 million at the end of 2025, a 47.3% increase from 2024, and a 69.8% decrease since 2020.

In the past 5 years, Molecular Partners' cash and equivalents has ranged from $70.44 million in 2024 to $150.99 million in 2020, and is currently $104.15 million as of their latest financial filing in 2025.

Over the last 6 years, Molecular Partners' book value per share changed from 0.00 in 2019 to -9.64 in 2025, a change of -964.2%.


Related Companies

Financial statements for NASDAQ:MOLN last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel